Barry David M, Koo Yeon, Norden Pieter R, Wylie Lyndsay A, Xu Ke, Wichaidit Chonlarat, Azizoglu D Berfin, Zheng Yi, Cobb Melanie H, Davis George E, Cleaver Ondine
From the Department of Molecular Biology and Center for Regenerative Science and Medicine (D.M.B., Y.K., K.X., D.B.A., O.C.) and Department of Pharmacology (C.W., M.H.C.), University of Texas Southwestern Medical Center, Dallas; Department of Medical Pharmacology and Physiology, University of Missouri, Columbia (P.R.N., G.E.D.); Department of Biology, University of North Carolina, Chapel Hill (L.A.W.); and Division of Experimental Hematology and Cancer Biology, Children's Hospital Research Foundation, University of Cincinnati, OH (Y.Z.).
Circ Res. 2016 Sep 16;119(7):810-26. doi: 10.1161/CIRCRESAHA.116.309094. Epub 2016 Aug 2.
Vascular tubulogenesis is essential to cardiovascular development. Within initial vascular cords of endothelial cells, apical membranes are established and become cleared of cell-cell junctions, thereby allowing continuous central lumens to open. Rasip1 (Ras-interacting protein 1) is required for apical junction clearance, as well as for regulation of Rho GTPase (enzyme that hydrolyzes GTP) activity. However, it remains unknown how activities of different Rho GTPases are coordinated by Rasip1 to direct tubulogenesis.
The aim of this study is to determine the mechanisms downstream of Rasip1 that drive vascular tubulogenesis.
Using conditional mouse mutant models and pharmacological approaches, we dissect GTPase pathways downstream of Rasip1. We show that clearance of endothelial cell apical junctions during vascular tubulogenesis depends on Rasip1, as well as the GTPase Cdc42 (cell division control protein 42 homolog) and the kinase Pak4 (serine/threonine-protein kinase 4). Genetic deletion of Rasip1 or Cdc42, or inhibition of Pak4, all blocks endothelial cell tubulogenesis. By contrast, inactivation of RhoA (Ras homologue gene family member A) signaling leads to vessel overexpansion, implicating actomyosin contractility in control of lumen diameter. Interestingly, blocking activity of NMII (nonmuscle myosin II) either before, or after, lumen morphogenesis results in dramatically different tubulogenesis phenotypes, suggesting time-dependent roles.
Rasip1 controls different pools of GTPases, which in turn regulate different pools of NMII to coordinate junction clearance (remodeling) and actomyosin contractility during vascular tubulogenesis. Rasip1 promotes activity of Cdc42 to activate Pak4, which in turn activates NMII, clearing apical junctions. Once lumens open, Rasip1 suppresses actomyosin contractility via inhibition of RhoA by Arhgap29, allowing controlled expansion of vessel lumens during embryonic growth. These findings elucidate the stepwise processes regulated by Rasip1 through downstream Rho GTPases and NMII.
血管微管生成对心血管发育至关重要。在内皮细胞的初始血管索内,顶端膜形成并清除细胞间连接,从而使连续的中央管腔得以开放。Rasip1(Ras相互作用蛋白1)是顶端连接清除以及Rho GTP酶(水解GTP的酶)活性调节所必需的。然而,Rasip1如何协调不同Rho GTP酶的活性以指导微管生成仍不清楚。
本研究的目的是确定Rasip1驱动血管微管生成的下游机制。
利用条件性小鼠突变模型和药理学方法,我们剖析了Rasip1下游的GTP酶途径。我们发现血管微管生成过程中内皮细胞顶端连接的清除依赖于Rasip1,以及GTP酶Cdc42(细胞分裂控制蛋白42同源物)和激酶Pak4(丝氨酸/苏氨酸蛋白激酶4)。Rasip1或Cdc42的基因缺失,或Pak4的抑制,均会阻断内皮细胞微管生成。相比之下,RhoA(Ras同源基因家族成员A)信号失活会导致血管过度扩张,提示肌动球蛋白收缩在管腔直径控制中起作用。有趣的是,在管腔形态发生之前或之后阻断非肌肉肌球蛋白II(NMII)的活性会导致截然不同的微管生成表型,表明其具有时间依赖性作用。
Rasip1控制不同的GTP酶池,进而调节不同的NMII池,以协调血管微管生成过程中的连接清除(重塑)和肌动球蛋白收缩。Rasip1促进Cdc42的活性以激活Pak4,Pak4进而激活NMII,清除顶端连接。一旦管腔开放,Rasip1通过Arhgap29抑制RhoA来抑制肌动球蛋白收缩,从而在胚胎生长过程中允许血管管腔的受控扩张。这些发现阐明了Rasip1通过下游Rho GTP酶和NMII调节的逐步过程。